DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Atiprimod
Atiprimod
Cancer Subtype Identification Using Somatic Mutation Data
Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in Vivo
Biological Pathways and in Vivo Antitumor Activity Induced by Atiprimod in Myeloma
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Investigating the Mechanism of Hepatocellular Carcinoma Progression by Constructing Genetic and Epigenetic Networks Using NGS Data Identification and Big Database Mining Method
Spotlight Review
Alteration of Epileptogenesis Genes
Stat3 Inhibition Augments the Immunogenicity of B-Cell Lymphoma Cells, Leading to Effective Antitumor Immunity
Orphan Drug Designation List
Milciclib and Sorafenib Synergistically Downregulate C-Myc to Suppress
Hallmarks of Gastrointestinal Neuroendocrine Tumours: Implications for Treatment
WO 2017/068349 Al 27 April 2017 (27.04.2017) P O P C T
Atiprimod Blocks STAT3 Phosphorylation and Induces Apoptosis in Multiple Myeloma Cells
Dehydrocrenatidine Is a Novel JAK Inhibitor
Stembook 2018.Pdf
Trends and Developments in the Pharmacological Treatment of Psoriasis
WO 2020/039060 A1 27 February 2020 (27.02.2020)
Customs Tariff - Schedule
Top View
WO 2016/049524 Al 31 March 2016 (31.03.2016) P O P C T
A Shining Light in the Darkness for the Treatment of Pancreatic Neuroendocrine Tumors
The Multi-Kinase Inhibitor Debio 0617B Reduces Maintenance and Self-Renewal of Primary Human AML CD34 Stem/Progenitor Cells
Orphan Drug Designation List
WO 2017/058768 Al 6 April 2017 (06.04.2017) W P O P C T
Emerging Trends in Neuroendocrine Tumor Management
UNIVERSIDAD AUTÓNOMA DE MADRID DEPARTAMENTO DE FARMACOLOGÍA Potencial Terapéutico De La Proteína Reguladora SOCS1 En Las
Cancer Subtype Identification Using Somatic Mutation Data
(12) Patent Application Publication (10) Pub. No.: US 2016/0106584 A1 ANDINO Et Al
Future Challenges
WO 2021/026099 A1 11 February 2021 (11.02.2021) W P O PCT
Open Full Page
WO 2013/132044 Al 12 September 2013 (12.09.2013) P O P C T
THERAPY CODES 4-Factor Concentrate F014 5A2A F017
STAT Transcription Factors in Hematopoiesis and Leukemogenesis: Opportunities for Therapeutic Intervention
6:55 to 7:30 Pm Angiogenesis As An
The Role of AKT During IL-3- Dependent Survival Signalling
Cancer Subtype Identification Using Somatic Mutation Data
(12) United States Patent (10) Patent No.: US 7.652,009 B2 Kim Et Al
Bone Marrow Stroma–Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
© Ferrata Storti Foundation
Downloads/STT/Caff2005f4pwsecured.Pdf
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
Pharmaceutical Appendix to the Tariff Schedule 2
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Expression Profiling Analysis Reveals Molecular Mechanism of Lnc00675 Downregulation Promoting Cell Apoptosis in Acute Myeloid Leukemia U937 Cells
STAT3-Activated GM-Csfra Translocates to the Nucleus and Protects CLL Cells from Apoptosis
Tumor-Related Interleukins: Old Validated Targets for New Anti-Cancer Drug Development Sarra Setrerrahmane1 and Hanmei Xu1,2*
Review Research
Kinase Inhibitors As Potential Agents in the Treatment of Multiple Myeloma
Anti-Inflammatory Library
Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
The Novel JAK Inhibitor AZD1480 Blocks STAT3 and FGFR3 Signaling, Resulting in Suppression of Human Myeloma Cell Growth and Survival
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Chapter 5 STAT3 Inhibitors in Cancer: a Comprehensive Update
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016
(12) United States Patent (10) Patent No.: US 8,088,794 B2 Kim Et Al
An Azaspirane Derivative Suppresses Growth and Induces Apoptosis of ER-Positive and ER-Negative Breast Cancer Cells Through